Αρχική World News Encorafenib, Cetuximab Combination Approved for Metastatic Colorectal Cancer

Encorafenib, Cetuximab Combination Approved for Metastatic Colorectal Cancer

, by NCI Staff

Colon Cancer Attacking Cell

Some people with metastatic colorectal cancer have a new treatment option, with FDA’s recent approval of the targeted drug encorafenib (Braftovi), in combination with another targeted therapy, cetuximab (Erbitux).

Credit: iStock

The Food and Drug Administration (FDA) has approved encorafenib (Braftovi) for the treatment of some patients with colorectal cancer. The approval covers the use of encorafenib in combination with cetuximab (Erbitux) in adults with metastatic colorectal cancer whose tumors have a specific mutation in the BRAF gene, called V600E, and who have already undergone at least one prior treatment regimen. 

Both drugs are targeted therapies. Cetuximab, which targets a protein known as EGFR, has already been approved to treat some patients with colorectal cancer. Until this new approval, encorafenib, which targets the BRAF protein, was only approved to treat patients with melanoma whose tumors had BRAF mutations. 

The new approval was based on findings from a large phase 3 clinical trial, BEACON CRC, that was sponsored by the drug’s manufacturer, Pfizer. 

The V600E mutation in the BRAF gene is found in about 10% of metastatic colorectal cancers and is associated with especially poor outcomes. “It’s definitely a group of patients who do not do well with the available therapies, so the availability of this drug combination is definitely a big step forward,” said Carmen Allegra, M.D., special advisor on gastrointestinal cancer therapeutics in NCI’s Division of Cancer Treatment and Diagnosis

BRAF inhibitors alone have been found to be of limited benefit for patients with BRAF-mutant colorectal cancer, Dr. Allegra explained. “It’s clear that if you just inhibit BRAF, the primary driver of the cancer, the cancer figures out a way around that.”

The BEACON CRC trial was designed to test whether combining targeted therapies to simultaneously block multiple components of the BRAF signaling pathway could improve outcomes in patients with metastatic BRAF-mutant colorectal cancer.

The trial investigators compared both a three-drug combination of encorafenib, cetuximab, and binimetinib (Mektovi) and a two-drug combination of encorafenib and cetuximab with standard chemotherapy plus cetuximab (the control arm). Both combinations were superior to standard treatment, and the two-drug combination was just as effective as the three-drug regimen.

Patients who received encorafenib and cetuximab had a median overall survival of 8.4 months compared with 5.4 months for patients in the control arm. Also, more patients who received the two-drug combination had reductions in the size of their tumors (a tumor response) than patients in the control arm: 20% versus 2%. 

The trial “is teaching us something about how to use these targeted therapies,” Dr. Allegra said.

The most common severe side effects in patients treated with encorafenib and cetuximab included fatigue and weakness. Other common reactions included nausea, rash, and diarrhea. 

Further details on encorafenib and cetuximab and the BEACON CRC trial were described in this November 2019 Cancer Currents article.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

The IGCCCG Update Model Allows Improved and More Granular Individual Prognostic Assessment in Metastatic Non-Seminomatous Germ Cell Tumours

A new web-based calculator based on the results of the International Germ Cell Cancer Collaborative Group (IGCCCG) Update analysis allows improved and more granular individual prognostic...

How Sharing My Story Helps Me Cope With an Advanced Brain Tumor Diagnosis

Tom Freeman is an audio technology professional working in Silicon Valley. At night, he is a music and video producer who works with various...

Percentage of Cancer Patients Who Are Eligible for and Respond to Genome-Targeted Therapy Modestly Increased Over Time

Dr. Alyson Haslam of the Department of Epidemiology and Biostatistics, University of California San Francisco in San Francisco, CA, US and colleagues reported on...

How to Find an Oncologist Who’s an LGBTQ+ Ally: An Expert Q&A

Charles Kamen, PhD, MPH, is a clinical psychologist and assistant professor at the University of Rochester Medical Center. Dr. Kamen has a strong background...

Sharing Energy

Do you have a favorite flower? It is very difficult for me to choose a favorite, for there is such a vast array of...

FDA Approves BCMA-Targeted CAR T-Cell Therapy for Multiple Myeloma

April 14, 2021, by NCI Staff Manufactured CAR T cells ready for infusion into a patient. Credit: Penn Medicine A type of immunotherapy called CAR T-cell therapy...